Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage
NCT07864480Phase 4Not yet recruiting
- Sponsor
- Southeast Retina Center
- Start
- Sep 2026
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
A Phase 4 trial of ranibizumab in proliferative diabetic retinopathy (PDR), Vitreous hemorrhage (VH), sponsored by Southeast Retina Center. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
ranibizumab
03
Conditions
proliferative diabetic retinopathy (PDR)Vitreous hemorrhage (VH)
Beyond the preview
Go deeper on NCT07864480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07864480.